Skip to Content

Clinical Trial News

This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.

Merck Provides Update on REVEAL Outcomes Study of Anacetrapib

Posted 2 days ago in Clinical Trials

KENILWORTH, N.J.--(BUSINESS WIRE) June 27, 2017 --Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib met its primary endpoint, significantly reducing major coronary events (defined as the composite of coronary death, myocardial infarction, and coronary...

Read more...

Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine

Posted 2 days ago in Clinical Trials

BOTHELL, Wash., June 27, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc., (NASDAQ:ALDR) today announced that eptinezumab, its lead product candidate for migraine prevention, met the primary and key secondary endpoints in PROMISE 1, a Phase 3 pivotal clinical trial evaluating patients with frequent episodic migraine. PROMISE 1 Highlights PROMISE 1 met the primary endpoint: highly statistically...

Read more...

Voyager Therapeutics Announces Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease

Posted 3 days ago in Clinical Trials

CAMBRIDGE, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced dosing of the first patient in a Phase 1 trial aimed at further optimizing the surgical delivery of VY-AADC01 for advanced Parkinson’s disease. This planned Phase 1 trial explores a posterior (i.e., b...

Read more...

FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

Posted 3 days ago in Clinical Trials

SAN DIEGO, June 26, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus' drug candidate IDN-7314 for the treatment of primary sclerosing cholangitis (PSC), a disease affecting bile ducts in the liver which can lead to cirrhosis and liver failure. The FDA's Orphan Drug Designation program is...

Read more...

TG Therapeutics Recaps Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 3rd Congress of the European Academy of Neurology

Posted 3 days ago in Clinical Trials

NEW YORK, June 26, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) recapped preliminary results from its ongoing Phase 2 study of TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis (RMS). The data was presented this past weekend at the 3rd Congress of the European Academy of Neurology (EAN), taking place in...

Read more...

Genentech’s Emicizumab Showed Positive Results in Phase III Studies (HAVEN 1 And HAVEN 2) in Hemophilia A With Inhibitors

Posted 4 days ago in Clinical Trials

South San Francisco, CA -- June 25, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive data from the primary analysis of the Phase III HAVEN 1 study in adults and adolescents and interim analysis of the Phase III HAVEN 2 study in children evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) for the treatment of hemophilia A with inhibitors to...

Read more...

New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

Posted 7 days ago in Clinical Trials

South San Francisco, CA -- June 22, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new post-hoc analyses from the Ocrevus (ocrelizumab) Phase III clinical trial program in people with relapsing and primary progressive forms of multiple sclerosis (RMS and PPMS) will be presented at the 3rd Congress of the European Academy of Neurology (EAN) from June 24 to June 27 in...

Read more...

GSK Presents Positive Results from Phase III Revaccination Study of its Candidate Shingles Vaccine Shingrix at CDC’s Advisory Meeting

Posted 8 days ago in Clinical Trials

London, UK June 21, 2017 -- Study conducted in individuals who had previously received currentstandard of care GSK [LSE/NYSE: GSK] today will be presenting new results from a clinical study showing that its candidate vaccine for the prevention of herpes zoster (shingles) in people aged 50 years or older, Shingrix (HZ/su), induces a strong immune response in older adults who have previously been vaccinated against...

Read more...

Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine

Posted 10 days ago in Clinical Trials

June 19, 2017 Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus (GBS) infection. An estimated 10 to 30 percent of pregnant women carry the GBS bacteria.1 In newborns, GBS manifests as sepsis, pneumonia, and meningitis,2 with potentially fatal outcomes for some, and...

Read more...

Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study

Posted 12 days ago in Clinical Trials

Copenhagen, Denmark; June 16, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today preliminary data from the ongoing Phase I/II study of tisotumab vedotin in solid tumors (GEN701). In Part 2 of the study, 11 of 34 evaluable patients in the cervical cancer cohort achieved a response; with a median time of treatment of 4.9 months, 7 responders are still ongoing or in follow up for progression. The safety p...

Read more...

Selecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout

Posted 2 weeks ago in Clinical Trials

WATERTOWN, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced data from its ongoing Phase 2 trial of SEL-212 (SVP-Rapamycin in combination with the uricase enzyme pegsiticase), which is being developed for patients with chronic...

Read more...

Kura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Posted 2 weeks ago in Clinical Trials

LA JOLLA, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that clinical and preclinical data for tipifarnib in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) was presented at the International Conference on Malignant Lymphoma (ICML) being...

Read more...

TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma

Posted 2 weeks ago in Clinical Trials

NEW YORK, June 14, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced updated clinical data from its ongoing Phase I/Ib trial of TGR-1202 (umbralisib), the Company's oral, next generation PI3K delta inhibitor, in combination with ibrutinib, a BTK inhibitor, in patients with Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). This study is being run in collaboration with the...

Read more...

Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and Ipilimumab

Posted 2 weeks ago in Clinical Trials

MENLO PARK, Calif., June 13, 2017 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that the University of Texas MD Anderson Cancer Center has dosed the first patient in a Phase 1 immunotherapy clinical trial investigating ipilimumab and evofosfamide for the treatment of patients with metastatic or...

Read more...

Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab

Posted 2 weeks ago in Clinical Trials

Tuesday, June 13, 2017 - Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP). Tanezumab is an investigational humanized monoclonal antibody that selectively targets, binds to and inhibits nerve...

Read more...

Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology

Posted 2 weeks ago in Clinical Trials

EMERYVILLE, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that results of its Phase 3 EASE LID clinical trial of ADS-5102 were published online in JAMA Neurology. A New Drug Application supporting ADS-5102 (amantadine) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) in people with Parkinson's disease is under review by the U.S....

Read more...

Lilly's Galcanezumab Significantly Reduces Number Of Migraine Headache Days For Patients With Migraine: New Results Presented At AHS

Posted 2 weeks ago in Clinical Trials

INDIANAPOLIS, June 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive results from three Phase 3 studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, including late-breaking data on several key secondary endpoints for galcanezumab compared to placebo at both studied doses. Detailed results from these studies (EVOLVE-1, EVOLVE-2...

Read more...

Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies

Posted 2 weeks ago in Clinical Trials

Saturday, June 10, 2017 - Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS MET and VERTIS SITA) of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes, met their primary endpoints. In the studies, both doses of...

Read more...

Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer

Posted 3 weeks ago in Clinical Trials

PLYMOUTH MEETING, Pa., June 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has commenced its phase 3 clinical program to evaluate the efficacy of Inovio’s DNA-based immunotherapy, VGX-3100, to treat cervical dysplasia caused by human papillomavirus (HPV). Inovio’s study will assess the efficacy of VGX-3100 in regressing cervical HSIL (high-grade squamous int...

Read more...

Cascadian Therapeutics' Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases

Posted 3 weeks ago in Clinical Trials

SEATTLE, June 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib, an investigational oral, small molecule kinase inhibitor that is highly selective for HER2 and the Company's lead product in development, has been granted orphan drug designation by the U.S. Food and Drug Administration ("FDA") for the treatment of breast...

Read more...
Older articles
Hide